MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 620 participants.

Also called NCT03961334

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 620 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03961334
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Greece, Norway, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03961334. Randomized; no masking; primary purpose prevention. Start 2019-12-05 (actual); primary completion 2025-01-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
Acronym
MOSES
Condition
Stroke, Ischemic
Intervention (Drug)
Dabigatran
Intervention (Drug)
Apixaban
Intervention (Drug)
Edoxaban
Intervention (Drug)
Aspirin
Intervention (Drug)
Clopidogrel
Lead sponsor
University of Zurich (class: other)
Collaborator
Swiss National Science Foundation (class: other)

Record details

Record id
cardio:ct-nct03961334
Content hash
a3d272fbbbe91f105dd8fdec20db1ef62da4d928a0efc3ef73818d8d1a036952